United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 4

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 4 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderGlaukos · 49

Strongest available pathGlaukos · +205.1%

Widest latest marginMiMedx Group · 11.6%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1GKOS · NYSE

Glaukos

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2001Laguna Hills, California$10.61B market cap

View full Companies Radar profile

49Cautious

Snapshot price$179.9as of page date

Monthly-close return+205.1%five-year window

FY2025 revenue$0.51BGLAUKOS Corp

Net margin-37.0%FY2025

P/E snapshot356.7xone ratio, not a verdict

Prism attention27.1%share across these five

Filing track recordRevenue, USD billions

+72.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 14.6%

52-week position90% through range

$73.16$191.6

News mentions1.4K

Community mentions11partial coverage

U.S.-scope patents486

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal82/100
Management stability90/100
Market position8/100
Capital-event signal30/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2PRCT · Nasdaq

PROCEPT BioRobotics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2009Redwood City, California$1.19B market cap

View full Companies Radar profile

48Cautious

Snapshot price$20.83as of page date

Monthly-close return-46.0%five-year window

FY2025 revenue$0.31BPROCEPT BioRobotics Corp

Net margin-31.0%FY2025

P/E snapshot-18.1xone ratio, not a verdict

Prism attention9.5%share across these five

Filing track recordRevenue, USD billions

+793.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 72.9%

52-week position16% through range

$16.66$42.43

News mentions492

Community mentions11partial coverage

U.S.-scope patents269

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal79/100
Management stability90/100
Market position0/100
Capital-event signal40/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3ANGO · Nasdaq

AngioDynamics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1988Latham, New York$655.1M market cap

View full Companies Radar profile

45Cautious

Snapshot price$15.85as of page date

Monthly-close return-44.2%five-year window

FY2025 revenue$0.29BANGIODYNAMICS INC

Net margin-11.6%FY2025

P/E snapshot-352.2xone ratio, not a verdict

Prism attention36.6%share across these five

Filing track recordRevenue, USD billions

+0.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021 · CAGR 0.1%

52-week position94% through range

$9.39$16.29

News mentions1.9K

Community mentions0partial coverage

U.S.-scope patents621

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal61/100
Management stability90/100
Market position21/100
Capital-event signal20/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 9 M&A involvements, 10 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4MDXG · Nasdaq

MiMedx Group

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1985Marietta, Georgia$655.9M market cap

View full Companies Radar profile

42Cautious

Snapshot price$4.50as of page date

Monthly-close return-69.4%five-year window

FY2025 revenue$0.42BMIMEDX GROUP, INC.

Net margin11.6%FY2025

P/E snapshot112.5xone ratio, not a verdict

Prism attention20.7%share across these five

Filing track recordRevenue, USD billions

+61.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.8%

52-week position30% through range

$3.03$7.97

News mentions1.1K

Community mentions9partial coverage

U.S.-scope patents431

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal41/100
Management stability90/100
Market position7/100
Capital-event signal57/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5TCMD · Nasdaq

Tactile Medical

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1995Minneapolis, Minnesota$524.6M market cap

View full Companies Radar profile

39Cautious

Snapshot price$23.16as of page date

Monthly-close return-48.0%five-year window

FY2025 revenue$0.33BTACTILE SYSTEMS TECHNOLOGY INC

Net margin5.8%FY2025

P/E snapshot21.6xone ratio, not a verdict

Prism attention6.1%share across these five

Filing track recordRevenue, USD billions

+58.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.2%

52-week position41% through range

$12.91$37.77

News mentions315

Community mentions0partial coverage

U.S.-scope patents24

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal65/100
Management stability90/100
Market position0/100
Capital-event signal15/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Glaukos

+205.1%

AngioDynamics

-44.2%

PROCEPT BioRobotics

-46.0%

Tactile Medical

-48.0%

MiMedx Group

-69.4%

Latest revenue

USD billions, official filing scope shown on each company card.

Glaukos

$0.51B

MiMedx Group

$0.42B

Tactile Medical

$0.33B

PROCEPT BioRobotics

$0.31B

AngioDynamics

$0.29B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

MiMedx Group

11.6%

Tactile Medical

5.8%

AngioDynamics

-11.6%

PROCEPT BioRobotics

-31.0%

Glaukos

-37.0%

Prism news attention

Normalized share across these five names; attention is not quality.

AngioDynamics

36.6%

Glaukos

27.1%

MiMedx Group

20.7%

PROCEPT BioRobotics

9.5%

Tactile Medical

6.1%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

AngioDynamics leads the conversation

It holds 36.6% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $0.29B.

Price path

Glaukos leads the available price paths

Its monthly-close return is +205.1% for the five-year window. At the other end, MiMedx Group is -69.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

MiMedx Group has the widest latest margin

Its FY2025 net margin is 11.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

AngioDynamics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -352.2x while its five-year window price return is -44.2%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · GKOS

Glaukos

1,397available Prism news records

Prism top themes

Price action & investor response

110

Earnings & financial performance

Capital allocation & transactions

Macro demand & rates

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+44.1%330 latest 12m vs 229 prior 12m

Machine-classified coverage tone

92.7% positive+2.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock price 41stock performance 31share price 28stock surge 25investment deal 16market reaction 13market response 11stock indices 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-10 · trend and themes shown through 2026-06

Areas of research · ANGO

AngioDynamics

1,892available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Macro demand & rates

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-29.5%256 latest 12m vs 363 prior 12m

Machine-classified coverage tone

91.2% positive+2.8 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 22vascetomy prostate cancer 15prostatic intraepithelial neoplasia 14earnings report 13diet prostate cancer 13age prostate cancer 11financial report 10market momentum 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-05–2026-06-30 · trend and themes shown through 2026-06

Areas of research · MDXG

MiMedx Group

1,067available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-19.2%97 latest 12m vs 120 prior 12m

Machine-classified coverage tone

86.8% positive-5.3 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

earnings report 11financial report 9stock performance 8stock price 7annual earnings 7share price 7device-biologic combination 6tissue regeneration 4

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-02–2026-06-02 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

GKOS

Glaukos

through 2026-04-30

Earnings releases 28Company announcements 3M&A 2Lawsuits 1Regulatory 1

2026-04-30
Earnings releases
The company reported net sales of $150.6 million for the quarter ended March 31, a 41% increase from the year-ago period on a reported basis and 39% on a constant-currency basis.
2026-04-17
Company announcements
EYECARE Glaukos Releases Its 2025 Sustainability Report, Highlighting Key Milestones Staff By ALISO VIEJO, Calif.—
2025-02-14
Lawsuits
Ivantis Inc. settled with Glaukos Corp. for $60 million to be paid in two installments, with the first $30 million due by Dec. 31, 2021, and the second $30 million by Dec. 31, 2022.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PRCT

PROCEPT BioRobotics

through 2025-11-04

Earnings releases 21Listing / IPO 4Leadership changes 1

2025-11-04
Earnings releases
Total revenue for the third quarter of 2025 was $83.3 million, an increase of 43% compared to the prior year period.
2025-10-31
Leadership changes
Larry Wood, the corporate vice president who helped build Edwards’ market-leading transcatheter aortic valve replacement business in his two decades with the company, left in September to become CEO of Procept BioRobotics.
2024-10-28
Listing / IPO
PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ANGO

AngioDynamics

through 2026-04-08

Earnings releases 24Asset acquisitions 5M&A 5Leadership changes 2Lawsuits 1

2026-04-08
Earnings releases
HC Wainwright also issued estimates for AngioDynamics’ Q2 2027 earnings at ($0.03) EPS.
2025-02-14
M&A
AngioDynamics has agreed to pay $1.75 million for certain assets of FlowMedica.
2025-02-14
Lawsuits
AngioDynamics (Queensbury, New York) reported the denial of cross-motions for summary judgment issued in the U.S. District Court in the Northern District of California in a patent litigation brought by VNUS Medical Technologies against Diomed (Andover, Massachusetts) AngioDynamics and Vascular Solutions (Minneapolis).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

MDXG

MiMedx Group

through 2026-04-16

Earnings releases 15Leadership changes 11Business contracts 3Company announcements 1Lawsuits 1

2026-04-16
Leadership changes
As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated.
2025-10-30
Earnings releases
Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year
2025-02-13
M&A
Alynx (Salt Lake City) completed its acquisition of MiMedx (Tampa, Florida), a development-stage company focusing on biomaterials for soft tissue repair.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TCMD

Tactile Medical

through 2025-08-04

Leadership changes 2Earnings releases 1Listing / IPO 1

2025-08-04
Earnings releases
Total revenue increased 7.8% year-over-year to $78.9 million
2025-01-16
Leadership changes
BiaCure™ Therapies Inc. proudly announces that its CEO, Laura King, has been appointed to the Board of Directors of Tactile Medical, a leading provider of medical devices for treating chronic conditions such as lymphedema and airway clearance.
2023-02-24
Listing / IPO
Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD) announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $13.00 per share.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 16–23. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Glaukos leads the readiness ranking

Its Prism readiness score is 49/100, the highest in this five-company comparison.

Open Glaukos in Companies Radar

Scale and margin leadership sit with Glaukos and MiMedx Group

Glaukos has the largest displayed latest revenue at $0.51B; MiMedx Group has the widest displayed latest margin at 11.6%.

Open Glaukos in Companies Radar Open MiMedx Group in Companies Radar

Comparisons

Strongest versus weakest available price path

Glaukos is +205.1% for its five-year window; MiMedx Group is -69.4% for its five-year window.

Open Glaukos in Companies Radar Open MiMedx Group in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.51B for Glaukos to $0.29B for AngioDynamics. Entity and filing-period labels remain visible on the company cards.

Open Glaukos in Companies Radar Open AngioDynamics in Companies Radar

Anomalies

AngioDynamics has the widest attention-readiness rank gap

It ranks #1 by measured news attention (36.6%) and #3 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open AngioDynamics in Companies Radar

PROCEPT BioRobotics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +793.6% while its available monthly-close return is -46.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open PROCEPT BioRobotics in Companies Radar

Explanations

Attention measures coverage volume, not quality

AngioDynamics's 36.6% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open AngioDynamics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Glaukos's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 49/100 score.

Open Glaukos in Companies Radar

Stress-test the largest divergence before forming a view

Compare PROCEPT BioRobotics's profile with Glaukos's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open PROCEPT BioRobotics in Companies Radar Open Glaukos in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.